ERBB2 and neoplasm: T-DXd effectively targets tumor cells that express low levels of HER2 and can deliver a potent cytotoxic payload through the bystander effect to neighboring tumor cells heterogeneously expressing HER2, unlike many other approved HER2-targeted therapies [43,44].